FDMT insider trading
NasdaqGS Healthcare4D Molecular Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Company website: www.4dmoleculartherapeutics.com
FDMT insider activity at a glance
FilingIQ tracks 164 insider transactions for FDMT in filings since Dec 17, 2020. The most recent transaction is dated Sep 16, 2026.
Across the full history, 5 open-market purchases
and 91 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on FDMT insider trades is 56.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest FDMT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for FDMT?
- FilingIQ tracks 164 Form 4 insider transactions for FDMT (4D Molecular Therapeutics, Inc.), covering filings from Dec 17, 2020 onwards. 17 of those are dated within the last 90 days.
- Are FDMT insiders net buyers or net sellers?
- Across the full Form 4 history for FDMT, 5 transactions (3%) were open-market purchases and 91 (55%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does FDMT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is FDMT in?
- 4D Molecular Therapeutics, Inc. (FDMT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $468.65M.
Methodology & sources
Every FDMT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.